CRISPR Therapeutics AG (LTS:0VRQ) Institutional Ownership: 62.31% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
43 GF Score
Price $48.29
GF Value $3.84
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Institutional Ownership?

CRISPR Therapeutics AG LTS:0VRQ +1.24% 43 Institutional Ownership is 62.31% as of Jul. 22, 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 43/100 and a GF Value™ of $3.84 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CRISPR Therapeutics AG's institutional ownership is 62.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CRISPR Therapeutics AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CRISPR Therapeutics AG's Float Percentage Of Total Shares Outstanding is 87.58%.

CRISPR Therapeutics AG Institutional Ownership Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Institutional Ownership Chart

CRISPR Therapeutics AG Historical Data

The historical data trend for CRISPR Therapeutics AG can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 64.94 62.78 63.34 64.42 64.25 64.44 65.71 63.87 63.74 62.31
LTS:0VRQ
43GF Score
CRISPR Therapeutics AG LTS:0VRQ
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 62.31% mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Institutional Ownership of 62.31% as of Jul. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Institutional Ownership too high?
CRISPR Therapeutics AG's current Institutional Ownership is 62.31%. Overall, CRISPR Therapeutics AG has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Institutional Ownership compare to ORKA and TVTX?
CRISPR Therapeutics AG's Institutional Ownership of 62.31% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Institutional Ownership is 62.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.84, compared to a current price of $48.29 — trading 1157.6% above its estimated fair value. The current Institutional Ownership is 62.31%. CRISPR Therapeutics AG's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Institutional Ownership is 62.31% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $48.29 is trading 1157.6% above its estimated GF Value™ of $3.84. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Institutional Ownership: 62.31%
  • GF Value™: $3.84 vs. price of $48.29 (1157.6% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
43GF Score

Get the complete analysis for LTS:0VRQ

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.29
Price
$3.84
GF Value